

EDITORIAL COMMENTS:

The authors should explain patients still using imatinib even they had criteria to change to second line therapy (leukemianet). Why this patients were still using imatinib after 1 year of treatment?

The conclusion is wrong. It shall not mention progression, prognosis and survival as it was not analysed at the paper (short follow-up). Longer follow- up is needed to reach this conclusions

AUTHOR'S FEEDBACK:

Thank you for your comments.

1. As regarding the use of a second line therapy, unfortunately at the time of the study the second and third generations tyrosine kinase inhibitors were not introduced into our institute. Therefore, we here evaluated imatinib (Gleevec) only.

2. I agree with your comment. So, I deleted the first section in the conclusion regarding disease progression and kept the section regarding progression of bone marrow fibrosis (highlighted). Our study evaluated progression of BM fibrosis not the progress of the disease itself. We also mentioned in the recommendation that a larger study with a large number of patients is needed and a study